Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.
Day temperature difference appears to influence lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH), such that the greater the difference, the worse the LUTS symptoms are and the higher the tendency to visit the emergency room is, a study reports.
The minimally invasive water vapour thermal therapy significantly reduced symptoms of benign prostatic hyperplasia (BPH), including lower urinary tract symptoms (LUTS) and urinary flow rate, and the improvements were sustained through to 5 years, according to long-term data released during the American Urological Association (AUA) 2020 Virtual Meeting.
Aquablation performs as well as transurethral resection of prostate (TURP) in terms of safety and efficacy for treating benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS), although the former is associated with a lower rate of retrograde ejaculation, according to the results of a systematic review.
The minimally invasive water vapour thermal therapy represents a viable approach for thermal ablative reduction of benign prostate hyperplasia (BPH), providing urinary symptom relief and quality of life improvement that are sustained over 4 years, a study has shown.
The selective α1A-adrenoceptor antagonist silodosin appears to safely and effectively reduce nocturia episodes in patients with benign prostatic hyperplasia (BPH), according to the results of an open-label trial.
The use of Aquablation in surgical prostate resection provides noninferior relief from benign prostate hyperplasia (BPH)-related lower urinary tract symptoms while reducing the risk of sexual dysfunction as compared with transurethral resection of the prostate (TURP), according to data from the WATER study.
The minimally invasive convective radiofrequency (RF) thermal therapy appears to provide early and durable relief of lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH), according to a team of US-based researchers. In addition, the procedure allows preservation of sexual function and can be performed on the median lobe and hyperplastic central zone tissue.
Use of alpha blockers, including silodosin, tamsulosin and alfuzosin, in the treatment of patients with benign prostatic hyperplasia is safe and effective in terms of improving lower urinary tract symptoms (LUTS) and quality of life (QoL), according to a study.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.